The PDK3 Knockout Raji Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphoblast cell line, engineered to disrupt the gene encoding pyruvate dehydrogenase kinase 3 (PDK3). This loss-of-function model enables systematic investigation of PDK3-mediated regulation of energy metabolism in a Burkitt lymphoma background. The product is supplied as a polyclonal pool, ensuring a diverse representation of genomic edits that collectively eliminate functional PDK3 expression while preserving the heterogeneous genetic landscape of the parental line. By abrogating PDK3-dependent phosphorylation and inactivation of the pyruvate dehydrogenase complex (PDC), these cells facilitate studies into the molecular control of glycolytic versus oxidative metabolic pathways, particularly under conditions of oncogenic stress or hypoxia that normally upregulate PDK3 activity.
The Raji host cell line originates from a Burkitt lymphoma, an aggressive B-cell malignancy, and is widely employed as a model system for B-lymphocyte biology, lymphomagenesis, and immune response mechanisms. These cells are transformed B lymphoblasts that exhibit rapid proliferation and characteristic metabolic features, including a high glycolytic rate analogous to the Warburg effect observed in many cancers. The Raji background offers a clinically relevant context for assessing PDK3 function, given the enzyme??s prominent role in metabolic reprogramming and its reported overexpression in various lymphoid and solid tumors. Consequently, PDK3 knockout in this environment provides a powerful experimental platform for dissecting metabolic dependencies that underpin B-cell lymphoma growth and survival.
PDK3 functions as an inhibitory kinase that phosphorylates the E1 ?? subunit (PDHA1) of the pyruvate dehydrogenase complex, thereby reducing the conversion of pyruvate to acetyl-CoA and attenuating tricarboxylic acid (TCA) cycle flux. This action shifts cellular metabolism toward aerobic glycolysis, facilitating biosynthesis and redox balance critical for proliferating cells. PDK3 is transcriptionally upregulated by key oncogenic and metabolic transcription factors, including HIF-1??, MYC, and FOXO1, and integrates signals from nutrient-sensing pathways such as AMPK, insulin signaling, and the PI3K/AKT/mTOR axis. The enzyme interacts with the E2 subunit of PDC and molecular chaperones like HSP90 to exert its regulatory function. Downstream, PDK3-mediated suppression of PDHA1 activity leads to increased lactate production and a metabolic profile that supports tumorigenesis, metastasis, and acquired drug resistance.
In the Raji lymphoblast context, elimination of PDK3 expression is expected to relieve PDC inhibition, thereby promoting pyruvate flux into the TCA cycle and enhancing mitochondrial oxidative phosphorylation at the expense of glycolytic lactate generation. This metabolic reversal may sensitize cells to mitochondrial-targeted therapies, reduce biosynthetic capacity, or alter apoptotic thresholds, providing mechanistic insights into B-cell lymphoma metabolism. The model is particularly suited for exploring the interplay between oncogenic signaling (e.g., MYC-driven transcription) and metabolic enzyme regulation, as well as for testing the hypothesis that PDK3 constitutes a metabolic vulnerability in highly glycolytic tumors. Researchers can employ this system to dissect signaling-metabolism crosstalk involving HIF-1??, AMPK, and PI3K/AKT/mTOR components.
Typical applications include detailed metabolic flux analyses using Seahorse extracellular flux assays (OCR/ECAR), PDH enzyme activity measurements, lactate production quantification, and immunoblotting for PDK3, PDHA1, and related pathway components. The knockout cells are also valuable for drug sensitivity profiling with PDK inhibitors (e.g., dichloroacetate) or standard-of-care chemotherapeutics, apoptosis and viability assays, and flow cytometric assessment of metabolic markers. Furthermore, the model supports RT-qPCR-based transcriptomics and immunofluorescence localization studies. By combining these experimental approaches, investigators can rigorously evaluate the impact of PDK3 disruption on the Warburg effect, hypoxic adaptation, and therapeutic resistance in B-cell malignancies. For further technical details or ordering information, please contact Ascent Research.
